Celcuity (CELC) surprised investors on Thursday with a narrower-than-expected net loss for the fourth quarter of 2025, leading to a more than 4% increase in its stock price. The clinical-stage biotech reported a net loss of $38.4 million ($0.73 per share), which, while deeper than the previous year’s $32.3 million, was significantly better than analysts’ projections of a $1.05 loss per share. Despite not generating revenue, the company’s disciplined spending and increased operating expenses of over $49 million were viewed positively.

The upcoming topline results from a phase 3 clinical trial of gedatolisib for advanced breast cancer, expected in the second quarter, add to the optimism surrounding Celcuity. The company has also bolstered its cash position, ending the quarter with nearly $166 million, providing a solid financial foundation for its ongoing research and development efforts.

For market professionals, Celcuity’s ability to manage expenses while preparing for critical trial results underscores its potential as a promising investment in the biotech sector.

Source: fool.com